Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688415 | 1.00 | CTSS (0.50) | CTSSCTSKCYP17A1FPR2PPARG | |
| SCHEMBL3379447 | 0.92 | CTSS (0.48) | CTSSCTSKFPR2PTPN11CA12 | |
| SCHEMBL3379450 | 0.92 | CTSS (0.48) | CTSSCTSKFPR2PTPN11CA12 | |
| SCHEMBL11574358 | 0.90 | CTSS (0.47) | CTSSCTSKCYP17A1FPR2S1PR3 | |
| SCHEMBL11574507 | 0.89 | CTSK (0.46) | CTSSCTSKCYP17A1FPR2PPARG | |
| SCHEMBL11573213 | 0.88 | CTSK (0.50) | CTSSCTSKFPR2PPARGPPARA | |
| SCHEMBL11573047 | 0.88 | CTSS (0.48) | CTSSCTSKCYP17A1FPR2S1PR3 | |
| SCHEMBL11872857 | 0.88 | CTSS (0.45) | CTSSCTSKFPR2S1PR3PTPN11 | |
| SCHEMBL11574050 | 0.88 | CTSS (0.45) | CTSSCTSKFPR2PTPN11CA12 | |
| SCHEMBL28503846 | 0.87 | TGM2 (0.46) | CTSSCTSKFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| EP-0090240-A2 | 7-Alpha-aminoacyl-3-chlorocephalosporins, their preparation and their use as pharmaceutical products | BAYER AG (DE) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885CYP17A1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.